Financial Press Releases

Loan amendment to enable conversion into ordinary shares
Loan amendment to enable conversion into ordinary shares
June 18, 2021

On 3 July 2018, the Company entered into a £1 million loan facility with Vulpes Investment Management Private Limited ("VIM") (the “Loan”).  On 30 March 2021, the Company announced that the Loan had been amended such that the Loan (of which £700,000 is currently drawn) and all accrued interest (£59,657 as at 31 May 2021) is now repayable on 1 May 2022 (“Drawn Loan”).

The Directors of the Company are now pleased to announce that the Loan has been amended such that until 30 April 2022, VIM may convert part (being not less than £50,000 or a multiple thereof) or all of the Drawn Loan and accrued interest to 31 December 2020 (being £51,538) into new ordinary shares of the Company (the “Loan Amendment”). 

Grant of Options and PDMR/director shareholdings
Grant of Options and PDMR/director shareholdings
June 8, 2021

Proteome Sciences announces the grant of options over new ordinary shares of 1p each in the Company (“Ordinary Shares”) under the Company’s share option schemes (“Options”). A total of 14,000,000 Options have today been issued to three directors of the Company.

Issuance of key TMT® Patent and Introduction of 18plex TMTpro™ Services
Issuance of key TMT® Patent and Introduction of 18plex TMTpro™ Services
May 20, 2021

Proteome Sciences is pleased to announce the issuance to it of U.S. Patent No. 10,976,321 relating to methods of analysis using isobaric mass tags.

Change of registered office
Change of registered office
May 18, 2021

The directors of Proteome Sciences announce that the Company’s registered office address has changed to 5 Dashwood Lang Road, Bourne Business Park, Addlestone, Surrey, KT15 2HJ with immediate effect.

 

Result of Annual General Meeting (AGM)
Result of Annual General Meeting (AGM)
May 5, 2021

Result of Annual General Meeting (AGM)

Annual General Meeting (AGM) Statement
Annual General Meeting (AGM) Statement
May 5, 2021

Annual General Meeting (AGM) Statement

Director/PDMR Shareholding
Director/PDMR Shareholding
April 19, 2021

The Company has received notification from Roger McDowell, a Director of the Company, that on 16 April 2021 he purchased 900,000 Ordinary Shares in the Company at a price of 5.00p per share.

Director/PDMR Shareholding
Director/PDMR Shareholding
April 14, 2021

The Company has received notification from Richard Dennis, Chief Commercial Officer, that on 12 April and 13 April 2021 he purchased, in aggregate, 625,000 Ordinary Shares in the Company at an average price of 5.22p per share. Richard Dennis now holds 625,000 Ordinary Shares in the Company, which represents approximately 0.21% of the issued share capital of the Company.

Annual Report and Financial Statements 31 December 2020
Annual Report and Financial Statements 31 December 2020
April 6, 2021

The Annual Report and Financial Statements for the year ended 31 December 2020, together with a notice of the Annual General Meeting is available to view on the Companies website www.proteomics.com and will be posted to shareholders imminently.

Holding(s) in Company
Holding(s) in Company
April 1, 2021

Holding(s) in Company - TR-1 notification was received from Helium Special Situations Fund on the 31 March 2021.